Lytix reports positive cancer data – plans larger trial

Norwegian biotech company Lytix Biopharma has reported positive phase II results for its drug candidate ruxotemitide in melanoma. The company is now aiming for ...

Child dies as measles cases surge across US

A child in New York has died from measles, Reuters reports, marking the first known measles-related death in the state in more than three decades. The death com...

Five doctors charged in Swedish prescription fraud scheme

Thirteen people, including five doctors, have been charged in a multi-million-krona fraud scheme in which a drug used to treat excessive sweating is suspected o...

Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”

BioArctic is losing out on potential milestone payments after Novartis decided to discontinue a research programme involving the Swedish company's BrainTranspor...

AstraZeneca drops two early-stage prostate cancer drugs

Two of AstraZeneca’s experimental prostate cancer treatments have come to an early end. The pharmaceutical company is discontinuing development of candidates AZ...

Major deal gives Fresenius access to 37 biosimilar candidates – “We are doubling down”

Fresenius and China's WuXi Biologics have signed an agreement that the German healthcare group describes as “the largest development agreement announced in the ...

Atlas Antibodies replaces CEO – brings in former OssDsign chief

Swedish biotech Atlas Antibodies is replacing its CEO, Dan Pitulia. He is succeeded by interim CEO Morten Henneveld.

They take the helm as Mölnlycke splits in two

Swedish medtech company Mölnlycke has appointed Anders Andersson as its new CEO and Fredrik Wallefors as head of its Surgical business area. The appointments co...

EU Biotech Act: Extended drug protection sparks debate

An extra year of protection for biotech medicines could boost investment in Europe – but also delay access to cheaper alternatives. The proposal is one of the m...

Alligator Bioscience sells mitazalimab – potential to receive more than 1 billion

Biotechnology company Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil, ac...

A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”

For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes a...

Eli Lilly drops Alzheimer’s drug candidate after phase II trial

Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expe...

AstraZeneca unveils major cost-cutting drive

AstraZeneca beat market expectations in the third quarter. At the same time, the company announced a cost-cutting programme expected to generate annual savings ...

Sobi proposes Börje Ekholm as new chair

Börje Ekholm, the former CEO of Ericsson, has been proposed as the new chair of Sobi.

Structured Dialogue with SGS Fimko – a clearer path through MDR and IVDR

Certification under MDR and IVDR involves complex regulatory requirements and important decisions regarding documentation and the conformity assessment process....

SynAct Pharma signs first dengue drug deal

SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.

Lilly’s triple-G drug outperforms Ozempic in head-to-head trial

Eli Lilly’s investigational drug retatrutide delivered more than twice the weight loss of rival Novo Nordisk’s Ozempic in a head-to-head phase 3 trial.

Ferring to buy IVF biotech in billion-dollar deal

Ferring has signed an agreement to acquire US biotechnology company Gameto in a deal worth up to $1.4 billion.

GRUBER aims to eliminate bottlenecks in pharmaceutical production

New welding solution aims to increase capacity and ensure quality in flip-off cap production

Danish drug candidate shows great response to two cancer types

Genmab’s hopes for petosemtamab have been boosted by positive phase II results in two cancer indications. The bispecific antibody showed promising efficacy in c...

Abbott sharpens cancer test – detects smaller traces of tumour DNA

A single tumour DNA molecule among more than a million others. That is how small a trace of cancer Abbott’s upgraded Oncodetect test is designed to detect in th...

Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off

US biotech company Artiva Biotherapeutics is discontinuing the development of a cell therapy for autoimmune diseases and laying off 94 per cent of its workforce...

Björn Ursing: “What happens when trust in science erodes?”

Medical breakthroughs have transformed healthcare, but scientific progress alone is not enough. As misinformation spreads and trust in science comes under press...

3button group AB